Test Price
2,800 AED✅ Home Collection Available
SLC34A1 Gene Nephrolithiasis/Osteoporosis, Hypophosphatemic Type 1 Genetic Test
Executive Summary & Core Metrics
Precision, Compliance & Patient‑Centric Care
- Diagnostic accuracy: 99.9% analytical sensitivity via ISO 9001:2015‑accredited processing (Certificate: INT/EGQ/2509DA/3139).
- Premium logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (daily 8 AM – 11 PM).
- Post‑test telecounseling: specialist interpretation and clinical correlation within 48 hours of report.
- Insurance verification: direct WhatsApp check at +971 54 548 8731.
Test Overview & Methodology
This next‑generation sequencing (NGS) assay provides comprehensive analysis of the SLC34A1 gene, detecting pathogenic variants that cause hypophosphatemic nephrolithiasis/osteoporosis type 1. Full gene coverage includes coding regions, splice sites, and selected intronic areas, enabling identification of novel mutations and copy number variants.
| Feature | Our Test (DHA‑Licenced Facility) | Conventional Single‑Variant Assay |
|---|---|---|
| Technology | NGS – full gene coverage including intronic boundaries | Sanger sequencing limited to known hot‑spots |
| Diagnostic Sensitivity | 99.9% analytical sensitivity, including CNV detection | ~80% for targeted variants only |
| Turnaround Time | 3–4 weeks | 4–6 weeks |
| Clinical Utility | Identifies novel mutations, supports family screening & personalised therapy | Re‑confirmed known familial variant only |
Physician Insight & Safety Protocols
“Genetic test results represent one piece of the diagnostic puzzle. Always correlate with serum phosphate, renal ultrasound, and bone densitometry. A negative result does not exclude other forms of hypophosphatemia. I urge patients to discuss findings with their nephrologist or endocrinologist before any treatment change.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Clinical Advisory
Medication Continuity Caution
Do not discontinue prescribed phosphate supplements, calcitriol, or any other medication without consulting your treating physician. Abrupt cessation can provoke severe metabolic imbalance. All clinical decisions must be made after comprehensive evaluation.
Exclusion Criteria & Emergency Red Flags
- This test is not a substitute for acute emergency care; it is elective and requires stable clinical status.
- Home collection cannot be performed if the patient has severe haemodynamic instability or uncontrolled pain.
- ER Red Flags: Sudden, severe flank pain with haematuria and fever; acute inability to pass urine; new‑onset tetany or seizures; suspected pathological fracture with neurovascular compromise. Seek immediate emergency attention.
Patient FAQ & Clinical Guidance
1. What does the SLC34A1 gene test detect and how is it clinically useful?
It identifies pathogenic mutations in the SLC34A1 gene that cause hypophosphatemic nephrolithiasis/osteoporosis type 1, enabling definitive diagnosis and targeted lifelong management of kidney stones and bone loss. Results guide phosphate supplementation, vitamin D therapy, and surveillance for renal complications.
2. Why is this test priced at 2,800 AED and what does the cost include?
The fee covers ISO‑accredited NGS full‑gene sequencing, pre‑test genetic counselling, VIP mobile phlebotomy with temperature‑controlled cold‑chain transport, and a comprehensive post‑test clinical interpretation report within 3–4 weeks. Insurance verification is available via WhatsApp.
3. Is this genetic test safe and legally protected for families in the UAE?
Yes. The test complies with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL), Federal Law No. 2 of 2019 on health data protection, and Federal Decree‑Law No. 4 of 2016 on Medical Liability. Informed consent is obtained, and all genetic data is encrypted and stored in UAE‑based servers.
UAE Regulatory & Data Privacy Adherence
This testing service operates under the regulatory oversight of the Dubai Health Authority (DHA) and complies with the following UAE federal laws:
- Federal Decree‑Law No. 45 of 2021 – Personal Data Protection Law (PDPL) governing collection, processing, and storage of patient genetic data.
- Federal Law No. 2 of 2019 – Use of Information and Communication Technology in Health Fields, ensuring digital health security and interoperability.
- Federal Decree‑Law No. 4 of 2016 – Medical Liability Law, defining patient consent, clinical safety, and professional accountability.
All genetic reports are reviewed and authorised by our consultant medical geneticist. Sample transport follows strict cold‑chain protocols with chain‑of‑custody documentation.
Clinical & Logistical Metadata
| Test Name | SLC34A1 Gene Nephrolithiasis/Osteoporosis, Hypophosphatemic Type 1 Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole blood (EDTA) – VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (daily 8 AM – 11 PM) |
| Methodology Used | Next‑Generation Sequencing (NGS) – full gene coverage including CNV detection |
| ICD-10-CM Code | E83.31 |
| LOINC Code | 89335-0 |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 | DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians